Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical raises $10M for Alzheimer’s drug trial

Actinogen Medical raises $10M for Alzheimer’s drug trial

Sydney based Actinogen Medical (ASX:ACW) has raised $10.0 million to further a trial of its very promising drug to fight Alzheimer’s disease.

The funds were raised in a placement which saw heavy investor demand at an issue price of $0.095 per share.

The Phase 2 trial of its drug Xanamem™ is planned to start in 2016 and for it to run in Australia/New Zealand, the USA and the UK.

Xanamem blocks cortisol production which is a key plank in the fight against Alzheimer's disease to stop the disease at an early stage.

Excess cortisol is associated with memory loss and amyloid plaques, hallmarks of Alzheimer’s disease.

The capital raising will also be used to support the IND filing with US FDA.

A share purchase plan will also raise an additional $1 million.

Alzheimer’s disease is the most common form of dementia and has a debilitating effect on patients and families. At present, there is no viable cure for sufferers.

Alzheimer’s is now the second leading cause of death in Australia behind ischaemic heart disease.

Estimates by the American Alzheimer’s Association indicate that the direct healthcare cost of the disease was $US250 billion in 2013.

This is projected to rise to over $US1 trillion by 2050, outstripping the cost of treating all other diseases.

 

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
test tubes
January 23 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
Summit
January 26 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use